Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganglioside-Monosialic Acid for Post-chemotherapy Cognitive Impairment in Breast Cancer
NCT05239663Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of monosialotetrahexosylganglioside in chemotherapy-induced cognitive impairment (CICI) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Hopkins Verbal Learning Test - Revised, Delayed Recall. Started Feb 2022; status: terminated.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
chemotherapy-induced cognitive impairment (CICI)
Beyond the preview
Go deeper on NCT05239663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239663.